Illumina (ILMN) EPS & PE Ratio History
Current and historical earning per share (EPS) and price to earnings (PE) ratio for Illumina (ILMN) over the last 10 years. The current PE ratio for Illumina as of August 18, 2017 is 57.72.
|Medical||Medical - Biomedical and Genetics||$27.641B||$2.398B|
|Illumina Inc. is a leading developer of next-generation tools for the large-scale analysis of genetic variation and function. The company's tools will provide information that could be used to improve drugs and therapies, customize diagnoses and treatment, and cure disease. The company is developing a comprehensive line of products that can address the scale of experimentation and the breadth of functional analysis required to achieve the goals of molecular medicine.|